Earlier this year, because of a delay in getting the site cleared, Genzyme scaled back its 2008 adjusted profit guidance by 10 cents to $3.90 a share. The company didn't change that guidance with its third-quarter earnings. Wall Street is expecting the company to earn $3.95 a share, on $4.66 billion in revenue, in 2008.
Watch for results from Amgen(AMGN Quote) after the market closes, and from Celgene(CELG Quote) on Thursday. Fellow biotech Biogen Idec(BIIB Quote) reported its third-quarter earnings on Tuesday. Shares of Genzyme were recently down 2% at $66.80.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,328.89 | 1,102.47 | 2,211.69 | 35.46 |
Oil *
73.88
|
|
UP
20.63
|
UP
6.40
|
UP
31.64
|
UP
0.59
|
10 Yr
3.55%
SPDR Gold
108.95
|
|
+0.20%
|
+0.58%
|
+1.45%
|
+1.69%
|
Data delayed 20 minutes |
